NASDAQ$CRIS
Curis Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Curis reported a net loss for Q3 2022 and focused its resources on advancing emavusertib development.
Curis reported a net loss of $13.3 million for the third quarter of 2022, compared to a net loss of $11.1 million for the same period in 2021. The company is prioritizing the development of emavusertib and expects its cash runway to extend into 2025.
- Curis is focusing its resources to drive the development of emavusertib.
- Cash runway extended into 2025 due to reallocation of resources.
- Data from the TakeAim Leukemia trial of emavusertib will be presented at ASH 2022.
- FDA allowed enrollment to resume in the TakeAim Lymphoma study and in the monotherapy dose finding phase of the TakeAim Leukemia study.
Headline financials
Revenue & EPS history
Curis · Revenue · Quarterly
$2.83M
Revenue by segment
Curis · $2.84M total across 1 segment · Q3 2022
- Royalties$2.84M-6.4%100.0%
Forward guidance
Curis expects that its existing cash, cash equivalents and investments should enable it to maintain its planned operations into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
-1.7%
Avg return
Earnings day
-1.2%
Avg return
5 days after
+14.9%
Avg return
30 days after
37%
23 / 63 earnings
Positive
+46.2%
Q4 2017
Best reaction
-26.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.3% | -4.6% | — | |
| Q1 2026 | -9.5% | -13.1% | -23.7% | |
| Q3 2025 | -7.2% | -15.8% | -7.5% | |
| Q4 2024 | -9.5% | -38.6% | -32.4% | |
| Q3 2024 | +0.5% | -3.6% | -9.2% | |
| Q2 2024 | -8.8% | -12.4% | +0.9% | |
| Q1 2024 | +1.1% | -2.8% | -40.2% | |
| Q4 2023 | +10.9% | +8.0% | +11.8% | |
| Q3 2023 | -3.0% | +15.3% | +151.8% | |
| Q2 2023 | -11.5% | -17.7% | -26.6% | |
| Q1 2023 | -0.6% | +2.5% | +6.2% | |
| Q4 2022 | -10.9% | -14.3% | +31.7% | |
| Q3 2022 | +5.1% | +15.4% | -1.3% | |
| Q2 2022 | +2.0% | +0.0% | -7.1% | |
| Q1 2022 | -12.6% | +2.0% | -6.0% | |
| Q4 2021 | +9.2% | +15.7% | -15.4% | |
| Q3 2021 | -0.7% | -2.5% | -21.1% | |
| Q2 2021 | -6.9% | -10.1% | +13.9% | |
| Q1 2021 | +33.0% | +53.1% | -18.5% | |
| Q4 2020 | -1.7% | +10.2% | +10.8% | |
| Q3 2020 | +12.0% | +13.9% | +647.2% | |
| Q2 2020 | +16.8% | +19.3% | -16.0% | |
| Q1 2020 | -12.0% | -10.5% | +55.8% | |
| Q4 2019 | -7.1% | -4.2% | +9.7% | |
| Q3 2019 | -26.3% | -39.1% | -24.3% | |
| Q2 2019 | -21.3% | -20.9% | -18.3% | |
| Q1 2019 | -1.6% | -11.4% | -22.7% | |
| Q4 2018 | +5.8% | +5.3% | -5.8% | |
| Q3 2018 | +5.5% | -1.8% | -47.2% | |
| Q2 2018 | -9.8% | -12.4% | -12.4% | |
| Q1 2018 | -10.8% | -12.5% | -11.1% | |
| Q4 2017 | +46.2% | +43.9% | -5.3% | |
| Q3 2017 | -11.3% | -18.5% | -44.4% | |
| Q2 2017 | +0.0% | -1.2% | +21.5% | |
| Q1 2017 | -11.7% | -7.9% | -10.7% | |
| Q4 2016 | +16.1% | +12.5% | +2.0% | |
| Q3 2016 | -3.6% | +11.1% | +20.2% | |
| Q2 2016 | -1.7% | +1.1% | -3.4% | |
| Q1 2016 | +7.3% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | -9.7% | — | — | |
| Q1 2015 | +4.6% | — | — | |
| Q4 2014 | +0.3% | — | — | |
| Q3 2014 | -0.8% | — | — | |
| Q2 2014 | -7.8% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +11.4% | — | — | |
| Q3 2013 | -25.2% | — | — | |
| Q2 2013 | +3.0% | — | — | |
| Q1 2013 | -9.4% | — | — | |
| Q4 2012 | -4.0% | — | — | |
| Q3 2012 | -3.4% | — | — | |
| Q2 2012 | -0.9% | — | — | |
| Q1 2011 | +2.9% | — | — | |
| Q1 2012 | +0.6% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q3 2011 | -6.8% | — | — | |
| Q3 2010 | -6.8% | — | — | |
| Q2 2011 | -10.6% | — | — | |
| Q2 2010 | -10.6% | — | — | |
| Q4 2010 | +2.4% | — | — | |
| Q1 2010 | -6.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro